A case report highlights the interest of a long-term treatment with ADV-7103 in dRTA

April 5, 2022

Paris, 5 April 2022 – 6.00 pm CEST – Advicenne (Euronext: ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces a case report published in Journal of Nephrology about a child partly recovering from growth retardation resulting from the long-term control of her metabolic acidosis with ADV-7103.